Gastric Adenocarcinoma
Conditions
Keywords
gastric adenocarcinoma, tumor markers, peritoneal cytology
Brief summary
For preoperative staging and prediction of peritoneal dissemination of gastric adenocarcinoma, usage of serum and peritoneal levels of carcinoembryonic antigen (CEA) and CA 19-9 may be helpful. Additionally, the prognosis of the patients with gastric adenocarcinoma treated with gastrectrectomy may be associated with serum and peritoneal levels of tumor markers.
Detailed description
Clinical usage of tumor markers on preoperative staging and prediction of peritoneal dissemination of gastric adenocarcinoma is a controversial issue. It has been thought that there is a positive correlation between serum and peritoneal levels of carcinoembryonic antigen (CEA) and CA 19-9 and pathologic features of gastric tumors and peritoneal dissemination. In this study, it was aimed to evaluate the effect of serum and peritoneal CEA and CA 19-9 to predict TNM stages and peritoneal washing cytology in patients with gastric adenocarcinoma after curative gastrectomy, and to determine predictive value of these measurements to the development of recurrence and death.
Interventions
PROCEDUREgastrectomy
radical total/subtotal gastrectomy with D2 lymph node dissection
PROCEDUREsampling of peritoneal washing aspirate
After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
Sponsors
Bezmialem Vakif University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Endoscopically proven gastric adenocarcinoma * Standard gastrectomy and a D2 lymph node dissection; * Desire to attend the study protocol
Exclusion criteria
* Metastatic or overt peritoneal disseminated cancer * Undesired reaction to attend the study protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| TNM stage | through pathologic report completion, an average of 1 month | TNM stage based on the 7th American Joint Committee on Cancer/International Union Against Cancer tumor, node, metastasis system. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| peritoneal washing cytology | through pathologic report completion, an average of 1 month | detection of positive free peritoneal gastric adenocarcinoma cells. |
| recurrence/death | through follow-up period, an average of 24 months | detection of recurrence or development of death |
Countries
Turkey (Türkiye)
Outcome results
None listed